| --- | --- | --- | |-------|-------|-------| | | | | | | | | | --- ...

MediWound Ltd. (NASDAQ:MDWD) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Ofer Gonen - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Bryan Bergin - Cowen Ryan Zimmerman - BTIG Arthur He - H.C. Wainwright Operator Good day and welcome to MediWound???s Second Quarter 2022 Earnings Call. Today???s conference is being recorded. At this time, I would like to turn the conference over to Monique Ko ...

Exhibit 99.2 MEDIWOUND LTD. AND ITS SUBSIDIARIES CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS INDEX | | Page | | --- | --- | | Condensed Interim Consolidated Statements of Financial Position | F-2 | | Condensed Interim Consolidated Statements of Profit or Loss and Other Comprehensive Income or Loss | F-3 | | Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficit) | F-4 – F-5 | | Condensed Interim Consolidated Statements of Cash Flows | F-6 – F-7 | | Notes to Condensed I ...

MediWound Ltd. (NASDAQ:MDWD) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Monique Kosse - IR Sharon Malka - CEO Boaz Gur-Lavie - Chief Financial Officer Ofer Gonen - Board Member Lior Rosenberg - Chief Medical Officer Cyaandi R. Dove - Investigator, Advanced Wound & Ankle Center, Las Vegas Conference Call Participants Unidentified Analyst - Cowen and Company Kevin DeGeeter - Oppenheimer Arthur He - H.C. Wainwright Operator Good day and welcome to the MediWound First Quarter ...

MediWound Ltd. (NASDAQ:MDWD) Q4 2021 Earnings Conference Call March 17, 2022 8:30 AM ET Company Participants Monique Kosse - Investor Relations Sharon Malka - Chief Executive Officer Boaz Gur-Lavie - Chief Financial Officer Conference Call Participants Josh Jennings - Cowen Kevin DeGeeter - Oppenheimer Ryan Zimmerman - BTIG Swayampakula Ramakanth - H.C. Wainwright Nathan Weinstein - Aegis Capital Operator Good day and thank you for standing by. Welcome to MediWound Fourth Quarter and Year End 2021 Conferenc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________________ to ____________________ OR ☐SHELL COMPANY REPORT PURS ...

Exhibit 99.1 MediWound Reports Fourth Quarter and Full Year 2021 Financial Results Full-Year 2021 Total Revenues of $23.8 Million; Product Revenues Up 46% Positive Top-Line Data for EscharEx Phase 2 Clinical Trial, with Full Data Set Anticipated in Second Quarter 2022 Raised Gross Proceeds of $10 Million through Public Equity Of ering Conference Call Begins Today at 8:30 am ET YAVNE, Israel, March 17, 2022 -- MediWound Ltd. (Nasdaq: MDWD) (the "Company"), a fully-integrated biopharmaceutical company focused ...

MediWound Ltd. (NASDAQ:MDWD) Q3 2021 Results Conference Call November 16, 2021 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors Sharon Malka - CEO Boaz Gur-Lavie - CFO Conference Call Participants Bryan Bergin - Cowen and Company Ryan Zimmerman - BTIG Kevin DeGeeter - Oppenheimer Swayampakula Ramakanth - H.C. Wainwright Operator Good day, and welcome to the MediWound Third Quarter 2021 Earnings Conference Call. Today's conference is being recorded. At this time, I would like to turn the call ...

Financial Data and Key Metrics Changes - Revenues for Q2 2021 increased 50% to $6.1 million compared to $4 million in Q2 2020 [23] - Product revenue for Q2 2021 was $3 million, a 175% increase from $1.1 million in Q2 2020, driven by BARDA procurement of NexoBrid [23] - Gross profit for Q2 2021 was $2.4 million or 39% of net revenue, compared to $1.2 million or 30% in Q2 2020 [24] - Net loss for Q2 2021 was $3.2 million or $0.12 per share, compared to a net loss of $3.1 million or $0.11 per share in Q2 2020 [25] - For the first half of 2021, revenue increased 41% to $11.9 million compared to $8.5 million in the first half of 2020 [26] Business Line Data and Key Metrics Changes - The EscharEx clinical development program showed positive interim assessment results, confirming no need for sample size adjustments [12] - NexoBrid's commercial growth is supported by BARDA procurement, with expectations to recognize most remaining revenues in 2021 [17] - The company continues to enroll patients in the expanded access program for NexoBrid, with over 100 burn victims treated to date [17] Market Data and Key Metrics Changes - The company is executing a global expansion strategy, expecting additional marketing approvals in lucrative markets over the next 18 months [17] - The pediatric investigational plan for NexoBrid showed positive top-line results from a Phase III study, reinforcing its clinical safety and efficacy profile [19] Company Strategy and Development Direction - The company aims to enhance global expansion and expects additional marketing approvals in new territories throughout 2022 [22] - MediWound is committed to bringing NexoBrid to the U.S. market as quickly as possible, addressing FDA concerns from the CRL [18] - The company is focused on advancing its clinical development programs, particularly for EscharEx and NexoBrid, while maintaining budget discipline [27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the long-term potential of NexoBrid and the prospects for EscharEx, highlighting a diversified pipeline [29] - The company is monitoring the impact of COVID-19 dynamics on its financial guidance for 2021 [28] Other Important Information - As of June 30, 2021, the company had $17.2 million in cash and short-term investments, down from $21.6 million at the end of 2020 [28] - The company plans to complete enrollment in the EscharEx Phase II study by the end of 2021, with data readout anticipated in the first half of 2022 [13] Q&A Session Summary Question: Update on regulatory process for NexoBrid in the U.S. - Management believes FDA concerns can be addressed without additional studies and is preparing for a Type A meeting with the FDA [30] Question: Regulatory strategy for pediatric population regarding NexoBrid - Any label extension in the U.S. will follow approval for the adult indication, leveraging pediatric data in the resubmission [31] Question: Update on expanded access protocol for NexoBrid - Currently, there are 21 active sites in the U.S., with plans to extend to up to 30 sites and treat at least 200 patients [34] Question: MediWound's role in BLA resubmission for NexoBrid - The collaboration with Vericel and BARDA is crucial, with Vericel taking a leadership role in the regulatory process [37] Question: Timing for starting the second pivotal trial for EscharEx - Enrollment for the ongoing Phase II study is expected to be completed by year-end, with data readout anticipated in the first half of 2022 [39]

May 2021 I Nasdaq: MDWD Company Presentation | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...